PreveCeutical Announces Date for Annual General and Special Meeting
PreveCeutical Medical (OTCQB: PRVCF) has scheduled its annual general and special meeting for August 15, 2025. Shareholders will vote on director elections, auditor appointments, and notably, a plan to distribute up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders.
The arrangement will result in shareholders owning stakes in two separate companies: BioGene, focusing on Dual Gene Therapy program development, and PreveCeutical, continuing its focus on preventive and curative therapies using organic products. This strategic separation aims to expand both companies' shareholder bases and improve access to capital for research and development.
PreveCeutical Medical (OTCQB: PRVCF) ha fissato la sua assemblea generale annuale e straordinaria per il 15 agosto 2025. Gli azionisti voteranno sull'elezione dei direttori, la nomina dei revisori dei conti e, in particolare, su un piano per distribuire fino a 12 milioni di azioni ordinarie di BioGene Therapeutics agli azionisti di PreveCeutical.
Questa operazione porter脿 gli azionisti a detenere partecipazioni in due societ脿 distinte: BioGene, focalizzata sullo sviluppo del programma di terapia genica duale, e PreveCeutical, che continuer脿 a concentrarsi su terapie preventive e curative basate su prodotti organici. Questa separazione strategica mira ad ampliare la base di azionisti di entrambe le societ脿 e a migliorare l'accesso ai capitali per la ricerca e lo sviluppo.
PreveCeutical Medical (OTCQB: PRVCF) ha programado su junta general anual y extraordinaria para el 15 de agosto de 2025. Los accionistas votar谩n sobre la elecci贸n de directores, la designaci贸n de auditores y, en particular, un plan para distribuir hasta 12 millones de acciones comunes de BioGene Therapeutics a los accionistas de PreveCeutical.
Este acuerdo resultar谩 en que los accionistas posean participaciones en dos compa帽铆as separadas: BioGene, enfocada en el desarrollo del programa de terapia g茅nica dual, y PreveCeutical, que continuar谩 centrada en terapias preventivas y curativas utilizando productos org谩nicos. Esta separaci贸n estrat茅gica busca ampliar la base de accionistas de ambas empresas y mejorar el acceso a capital para investigaci贸n y desarrollo.
PreveCeutical Medical (OTCQB: PRVCF)电� 2025雲� 8鞗� 15鞚�鞐� 鞐半 氚� 韸闺硠 欤检＜齑濏殞毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 欤检＜霌れ潃 鞚挫偓 靹犾瀯, 臧愳偓 靹犾瀯, 攴鸽Μ瓿� 韸鬼瀳 PreveCeutical 欤检＜霌れ棎瓴� BioGene Therapeutics鞚� 1,200毵� 氤错喌欤�毳� 氚半秳頃樀鐢 瓿勴殟鞐� 雽�頃� 韴憸頃� 鞓堨爼鞛呺媹雼�.
鞚� 臁办箻电� 欤检＜霌れ澊 霊� 臧滌潣 氤勲弰 須岇偓鞐� 歆�攵勳潉 氤挫湢頃橁矊 頃樀鐢雿�, BioGene鞚� 鞚挫 鞙犾爠鞛� 旃橂 頂勲攴鸽灗 臧滊皽鞐� 歆戩頃橂┌, PreveCeutical电� 鞙犼赴雴� 鞝滍拡鞚� 頇滌毄頃� 鞓堧癌 氚� 旃橂 鞖旊矔鞐� 瓿勳啀 欤茧牓頃� 瓴冹瀰雼堧嫟. 鞚措煬頃� 鞝勲灥鞝� 攵勲Μ电� 霊� 須岇偓鞚� 欤检＜ 旮半皹鞚� 頇曤寑頃橁碃 鞐瓣惮 臧滊皽鞚� 鞙勴暅 鞛愲掣 鞝戧芳靹膘潉 頄レ儊鞁滍偆电� 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
PreveCeutical Medical (OTCQB : PRVCF) a programm茅 son assembl茅e g茅n茅rale annuelle et extraordinaire pour le 15 ao没t 2025. Les actionnaires voteront sur l鈥櫭﹍ection des administrateurs, la nomination des auditeurs et, notamment, sur un plan visant 脿 distribuer jusqu鈥櫭� 12 millions d鈥檃ctions ordinaires de BioGene Therapeutics aux actionnaires de PreveCeutical.
Cette op茅ration conduira les actionnaires 脿 d茅tenir des parts dans deux soci茅t茅s distinctes : BioGene, sp茅cialis茅e dans le d茅veloppement du programme de th茅rapie g茅nique double, et PreveCeutical, qui poursuivra son focus sur les th茅rapies pr茅ventives et curatives utilisant des produits biologiques. Cette s茅paration strat茅gique vise 脿 茅largir la base d鈥檃ctionnaires des deux entreprises et 脿 am茅liorer l鈥檃cc猫s aux capitaux pour la recherche et le d茅veloppement.
PreveCeutical Medical (OTCQB: PRVCF) hat seine j盲hrliche Haupt- und Sonderversammlung f眉r den 15. August 2025 angesetzt. Die Aktion盲re werden 眉ber die Wahl der Direktoren, die Ernennung der Wirtschaftspr眉fer und insbesondere 眉ber einen Plan abstimmen, bis zu 12 Millionen Stammaktien von BioGene Therapeutics an die PreveCeutical-Aktion盲re zu verteilen.
Diese Vereinbarung f眉hrt dazu, dass die Aktion盲re Anteile an zwei getrennten Unternehmen halten: BioGene, das sich auf die Entwicklung des Dual-Gentherapie-Programms konzentriert, und PreveCeutical, das weiterhin seinen Fokus auf pr盲ventive und kurative Therapien mit organischen Produkten legt. Diese strategische Trennung zielt darauf ab, die Aktion盲rsbasis beider Unternehmen zu erweitern und den Zugang zu Kapital f眉r Forschung und Entwicklung zu verbessern.
- Strategic separation will allow for more focused investment opportunities in specific business segments
- Potential for improved access to capital for both companies' research and development
- Shareholders will maintain ownership in both companies post-distribution
- None.
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve:
the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors of the Company;
the ratification of the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the auditors of PreveCeutical for the financial year ending December 31, 2024, and 2025;
a plan of arrangement under the provisions of Division 5 of Part 9 of the Business Corporations Act (British Columbia), pursuant to which the Company will distribute up to 12,000,000 common shares of BioGene Therapeutics Inc. ("BioGene") to the PreveCeutical Shareholders; (the "Arrangement and Distribution") and
the adoption of the PreveCeutical's Omnibus Equity Incentive Plan.
Once the Arrangement and Distribution is complete, the PreveCeutical Shareholders will own shares in two companies: BioGene, which will focus on the development of the Dual Gene Therapy program, and PreveCeutical, which will continue to focus on developing innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical believes that the Arrangement and Distribution is in the best interests of PreveCeutical and the PreveCeutical Shareholders for numerous reasons, including that separating PreveCeutical and BioGene will expand both PreveCeutical's and BioGene's potential shareholder base and access to capital for research, development and clinical trials by allowing investors that want specific ownership in the particular business of BioGene the opportunity to invest directly in BioGene rather than through PreveCeutical.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website or follow us on and .
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669 Or
Investor Relations [email protected]
Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit
FAQ
When is PreveCeutical's (PRVCF) annual general meeting scheduled for 2025?
How many BioGene Therapeutics shares will be distributed to PreveCeutical shareholders?
What will be the focus areas of PreveCeutical and BioGene after the separation?
Who are the proposed directors for PreveCeutical's board in 2025?
What is the purpose of PreveCeutical's separation from BioGene Therapeutics?
